iScience (Jan 2023)
Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19
- Louise Pierneef,
- Anouk van Hooij,
- Danielle de Jong,
- Elisa M. Tjon Kon Fat,
- Krista E. van Meijgaarden,
- Elisa Petruccioli,
- Valentina Vanini,
- Anna H.E. Roukens,
- Delia Goletti,
- Paul L.A.M. Corstjens,
- Simone A. Joosten,
- Annemieke Geluk,
- M.S. Arbous,
- B.M. van den Berg,
- S. Cannegieter,
- C.M. Cobbaert,
- A. van der Does,
- J.J.M. van Dongen,
- J. Eikenboom,
- M.C.M. Feltkamp,
- A. Geluk,
- J.J. Goeman,
- M. Giera,
- T. Hankemeier,
- M.H.M. Heemskerk,
- P.S. Hiemstra,
- C.H. Hokke,
- J.J. Janse,
- S.P. Jochems,
- S.A. Joosten,
- M. Kikkert,
- L. Lamont,
- J. Manniën,
- T.H.M. Ottenhoff,
- M.R. del Prado,
- N. Queralt Rosinach,
- M. Roestenberg,
- M. Roos,
- A.H.E. Roukens,
- H.H. Smits,
- E.J. Snijder,
- F.J.T. Staal,
- L.A. Trouw,
- R. Tsonaka,
- A. Verhoeven,
- L.G. Visser,
- J.J.C. de Vries,
- D.J. van Westerloo,
- J. Wigbers,
- H.J. van der Wijk,
- R.C. van Wissen,
- M. Wuhrer,
- M. Yazdanbakhsh,
- M. Zlei
Affiliations
- Louise Pierneef
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands
- Anouk van Hooij
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands
- Danielle de Jong
- Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands
- Elisa M. Tjon Kon Fat
- Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands
- Krista E. van Meijgaarden
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands
- Elisa Petruccioli
- National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy
- Valentina Vanini
- National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy
- Anna H.E. Roukens
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands
- Delia Goletti
- National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy
- Paul L.A.M. Corstjens
- Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands
- Simone A. Joosten
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands
- Annemieke Geluk
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands; Corresponding author
- M.S. Arbous
- B.M. van den Berg
- S. Cannegieter
- C.M. Cobbaert
- A. van der Does
- J.J.M. van Dongen
- J. Eikenboom
- M.C.M. Feltkamp
- A. Geluk
- J.J. Goeman
- M. Giera
- T. Hankemeier
- M.H.M. Heemskerk
- P.S. Hiemstra
- C.H. Hokke
- J.J. Janse
- S.P. Jochems
- S.A. Joosten
- M. Kikkert
- L. Lamont
- J. Manniën
- T.H.M. Ottenhoff
- M.R. del Prado
- N. Queralt Rosinach
- M. Roestenberg
- M. Roos
- A.H.E. Roukens
- H.H. Smits
- E.J. Snijder
- F.J.T. Staal
- L.A. Trouw
- R. Tsonaka
- A. Verhoeven
- L.G. Visser
- J.J.C. de Vries
- D.J. van Westerloo
- J. Wigbers
- H.J. van der Wijk
- R.C. van Wissen
- M. Wuhrer
- M. Yazdanbakhsh
- M. Zlei
- Journal volume & issue
-
Vol. 26,
no. 1
p. 105873
Abstract
Summary: Diagnostic services for tuberculosis (TB) are not sufficiently accessible in low-resource settings, where most cases occur, which was aggravated by the COVID-19 pandemic. Early diagnosis of pulmonary TB can reduce transmission. Current TB-diagnostics rely on detection of Mycobacterium tuberculosis (Mtb) in sputum requiring costly, time-consuming methods, and trained staff. In this study, quantitative lateral flow (LF) assays were used to measure levels of seven host proteins in sera from pre-COVID-19 TB patients diagnosed in Europe and latently Mtb-infected individuals (LTBI), and from COVID-19 patients and healthy controls. Analysis of host proteins showed significantly lower levels in LTBI versus TB (AUC:0 · 94) and discriminated healthy individuals from COVID-19 patients (0 · 99) and severe COVID-19 from TB. Importantly, these host proteins allowed treatment monitoring of both respiratory diseases. This study demonstrates the potential of non-sputum LF assays as adjunct diagnostics and treatment monitoring for COVID-19 and TB based on quantitative detection of multiple host biomarkers.
